The association of serum IL-33/ST2 expression with hepatocellular carcinoma
Abstract Background IL-33 is a multifunctional cytokine with dual functions. However, the clinicopathological and prognostic significance of IL-33 in cancer patients, especially in patients with hepatocellular carcinoma (HCC), remains controversial. Therefore, we conducted a study of 565 patients wi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-11179-5 |
| _version_ | 1797769423520530432 |
|---|---|
| author | Xiaolan Pan Jinfeng Liu Meiqin Li Yihua Liang Zhimin Liu Ming Lao Min Fang |
| author_facet | Xiaolan Pan Jinfeng Liu Meiqin Li Yihua Liang Zhimin Liu Ming Lao Min Fang |
| author_sort | Xiaolan Pan |
| collection | DOAJ |
| description | Abstract Background IL-33 is a multifunctional cytokine with dual functions. However, the clinicopathological and prognostic significance of IL-33 in cancer patients, especially in patients with hepatocellular carcinoma (HCC), remains controversial. Therefore, we conducted a study of 565 patients with HCC and 561 healthy controls and performed a meta-analysis to quantitatively evaluate the above problems. Methods We collected blood from 565 patients with HCC and 561 healthy controls. ELISA was used to detect the concentrations of IL-33 and ST2 in the serum, and RT‒PCR was used to detect the levels of IL-33 and ST2 mRNA. Meanwhile, we collected comprehensive literature on IL-33 and the clinical characteristics of cancer patients retrieved from the PubMed, Web of Science and CNKI databases as of December 2022. An odds ratio (OR) with a 95% confidence interval (CI) was used to estimate the impact through overall and stratified analyses. Results Compared with the healthy control group, the levels of ST2 mRNA and serum in the peripheral blood of HCC patients increased (p < 0.05), while the levels of IL-33 mRNA and serum showed no significant difference between the two groups (p > 0.05). In the meta-analysis section, at the tissue level, the overall analysis showed that the expression of IL-33 was positively correlated with tumor stage, histological grade, distant metastasis, and tumor size. Compared with patients with low IL-33 expression, the 3-year overall survival (OS) rate (OR = 3.467, p < 0.001) and 5-year OS rate (OR = 2.784, p < 0.001) of patients with high IL-33 expression were lower. At the serum expression level, the overall analysis showed that the expression of IL-33 increased the risk of cancer, and the serum level of IL-33 was positively correlated with tumor stage and vascular invasion. Conclusion IL-33/ST2 is a useful predictive or prognostic biomarker in clinical evaluation and may be used as a potential therapeutic target, but much research is needed to verify this hypothesis. |
| first_indexed | 2024-03-12T21:08:49Z |
| format | Article |
| id | doaj.art-372c299f37044143ac0916df6aa27ef3 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-12T21:08:49Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-372c299f37044143ac0916df6aa27ef32023-07-30T11:17:46ZengBMCBMC Cancer1471-24072023-07-0123111510.1186/s12885-023-11179-5The association of serum IL-33/ST2 expression with hepatocellular carcinomaXiaolan Pan0Jinfeng Liu1Meiqin Li2Yihua Liang3Zhimin Liu4Ming Lao5Min Fang6Department of Clinical Laboratory, Guangxi Medical University Cancer HospitalDepartment of Clinical Laboratory, Guangxi Medical University Cancer HospitalDepartment of Clinical Laboratory, Guangxi Medical University Cancer HospitalDepartment of Clinical Laboratory, Guangxi Medical University Cancer HospitalDepartment of Clinical Laboratory, Guangxi Medical University Cancer HospitalDepartment of Clinical Laboratory, Guangxi Medical University Cancer HospitalDepartment of Clinical Laboratory, Guangxi Medical University Cancer HospitalAbstract Background IL-33 is a multifunctional cytokine with dual functions. However, the clinicopathological and prognostic significance of IL-33 in cancer patients, especially in patients with hepatocellular carcinoma (HCC), remains controversial. Therefore, we conducted a study of 565 patients with HCC and 561 healthy controls and performed a meta-analysis to quantitatively evaluate the above problems. Methods We collected blood from 565 patients with HCC and 561 healthy controls. ELISA was used to detect the concentrations of IL-33 and ST2 in the serum, and RT‒PCR was used to detect the levels of IL-33 and ST2 mRNA. Meanwhile, we collected comprehensive literature on IL-33 and the clinical characteristics of cancer patients retrieved from the PubMed, Web of Science and CNKI databases as of December 2022. An odds ratio (OR) with a 95% confidence interval (CI) was used to estimate the impact through overall and stratified analyses. Results Compared with the healthy control group, the levels of ST2 mRNA and serum in the peripheral blood of HCC patients increased (p < 0.05), while the levels of IL-33 mRNA and serum showed no significant difference between the two groups (p > 0.05). In the meta-analysis section, at the tissue level, the overall analysis showed that the expression of IL-33 was positively correlated with tumor stage, histological grade, distant metastasis, and tumor size. Compared with patients with low IL-33 expression, the 3-year overall survival (OS) rate (OR = 3.467, p < 0.001) and 5-year OS rate (OR = 2.784, p < 0.001) of patients with high IL-33 expression were lower. At the serum expression level, the overall analysis showed that the expression of IL-33 increased the risk of cancer, and the serum level of IL-33 was positively correlated with tumor stage and vascular invasion. Conclusion IL-33/ST2 is a useful predictive or prognostic biomarker in clinical evaluation and may be used as a potential therapeutic target, but much research is needed to verify this hypothesis.https://doi.org/10.1186/s12885-023-11179-5IL-33ST2Hepatocellular carcinomaPrognosisMetaCancer risk |
| spellingShingle | Xiaolan Pan Jinfeng Liu Meiqin Li Yihua Liang Zhimin Liu Ming Lao Min Fang The association of serum IL-33/ST2 expression with hepatocellular carcinoma BMC Cancer IL-33 ST2 Hepatocellular carcinoma Prognosis Meta Cancer risk |
| title | The association of serum IL-33/ST2 expression with hepatocellular carcinoma |
| title_full | The association of serum IL-33/ST2 expression with hepatocellular carcinoma |
| title_fullStr | The association of serum IL-33/ST2 expression with hepatocellular carcinoma |
| title_full_unstemmed | The association of serum IL-33/ST2 expression with hepatocellular carcinoma |
| title_short | The association of serum IL-33/ST2 expression with hepatocellular carcinoma |
| title_sort | association of serum il 33 st2 expression with hepatocellular carcinoma |
| topic | IL-33 ST2 Hepatocellular carcinoma Prognosis Meta Cancer risk |
| url | https://doi.org/10.1186/s12885-023-11179-5 |
| work_keys_str_mv | AT xiaolanpan theassociationofserumil33st2expressionwithhepatocellularcarcinoma AT jinfengliu theassociationofserumil33st2expressionwithhepatocellularcarcinoma AT meiqinli theassociationofserumil33st2expressionwithhepatocellularcarcinoma AT yihualiang theassociationofserumil33st2expressionwithhepatocellularcarcinoma AT zhiminliu theassociationofserumil33st2expressionwithhepatocellularcarcinoma AT minglao theassociationofserumil33st2expressionwithhepatocellularcarcinoma AT minfang theassociationofserumil33st2expressionwithhepatocellularcarcinoma AT xiaolanpan associationofserumil33st2expressionwithhepatocellularcarcinoma AT jinfengliu associationofserumil33st2expressionwithhepatocellularcarcinoma AT meiqinli associationofserumil33st2expressionwithhepatocellularcarcinoma AT yihualiang associationofserumil33st2expressionwithhepatocellularcarcinoma AT zhiminliu associationofserumil33st2expressionwithhepatocellularcarcinoma AT minglao associationofserumil33st2expressionwithhepatocellularcarcinoma AT minfang associationofserumil33st2expressionwithhepatocellularcarcinoma |